William D. Claypool

Shire ViroPharma, Inc. develops and manufactures drugs. It offers treatment for prophylaxis of hereditary angioedema, as well as capsules for the treatment of antibiotic associated pseudomembranous colitis caused by Clostridium difficile infection (CDI) and enterocolitis. The company was founded by Claude H. Nash and Mark A. McKinlay in September 1994 and is headquartered in Exton, PA.

3-Dimensional Pharmaceuticals, Inc. was acquired by Johnson & Johnson. 3-Dimensional Pharmaceuticals, Inc. operates as a drug discovery and development company that has a pipeline of drug candidates in the areas of cancer and inflammation, and metabolic and cardiovascular diseases

Morphotek, Inc. operates as a biotechnology company. It develops and distributes biopharmaceutical products. The firm leverages its Morphodoma and Libradoma platform technologies to develop and research a pipeline of preclinical and clinical stage monoclonal antibodies for the treatment of cancer, inflammation and infectious diseases. The company was founded by Nicholas C. Nicolaides, Luigi Grasso and Philip M. Sass in May 2000 and is headquartered in Exton, PA.

Phoenix Data Systems, Inc. provides electronic data capture and data management services for the pharmaceutical industries. Its services include reporting, training, and coding. The company was founded in 1997 and is headquartered in King of Prussia, PA.

The Gi Company Inc. develops drugs to treat gastrointestinal and related diseases. It offers intestinal trefoil factor for the treatment of oral mucositis. The company also has projects in enteritis, proctitis, inflammatory bowel disease, erosive gastro esophageal reflux disease, peptic ulcer disease and gastrointestinal motility disorders, as well as clinical programs in erosive gastritis, ulcerative colitis and corneal wound healing. The company was founded in 1998 and is headquartered in Framingham, MA.

Pennmark Associates LLC engaged in wholesaling pharmaceutical products. The company was headquartered in Wayne, PA.

Hsiri Therapeutics LLC engages in the discovering and developing therapies for infections due to drug resistant bacteria. Its research efforts are focuses on two major areas including infections due to mycobacteria and infections due to usual bacterial pathogens. The firm also developing compounds aimed at traditional bacterial infections caused by drug resistant bacteria. The company was founded by Dennis F. Willson and is headquartered in Media, PA.